The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.


Epithelial cells in the field of lung injury can give rise to distinct premalignant lesions that may bear unique genetic aberrations. A subset of these lesions may escape immune surveillance and progress to invasive cancer; however, the mutational landscape that may predict progression has not been determined. Knowledge of premalignant lesion composition and the associated microenvironment is critical for understanding tumorigenesis and the development of effective preventive and interception strategies. To identify somatic mutations and the extent of immune cell infiltration in adenomatous premalignancy and associated lung adenocarcinomas, we sequenced exomes from 41 lung cancer resection specimens, including 89 premalignant atypical adenomatous hyperplasia lesions, 15 adenocarcinomas <i>in situ</i>, and 55 invasive adenocarcinomas and their adjacent normal lung tissues. We defined nonsynonymous somatic mutations occurring in both premalignancy and the associated tumor as progression-associated mutations whose predicted neoantigens were highly correlated with infiltration of CD8<sup>+</sup> and CD4<sup>+</sup> T cells as well as upregulation of PD-L1 in premalignant lesions, suggesting the presence of an adaptive immune response to these neoantigens. Each patient had a unique repertoire of somatic mutations and associated neoantigens. Collectively, these results provide evidence for mutational heterogeneity, pathway dysregulation, and immune recognition in pulmonary premalignancy.<b>Significance:</b> These findings identify progression-associated somatic mutations, oncogenic pathways, and association between the mutational landscape and adaptive immune responses in adenomatous premalignancy.<i>See related commentary by Merrick, p. 4811</i>.

  • Aberle DR
  • Dubinett SM
  • Elashoff DA
  • Fishbein GA
  • Fishbein MC
  • Gardner BK
  • Grimes BS
  • Krysan K
  • Lee JM
  • Salehi-Rad R
  • Seki A
  • Sharma S
  • Spira AE
  • Tran LM
  • Wallace WD
  • Walser TC
  • Yanagawa J
PubMed ID
Appears In
Cancer Res, 2019, 79 (19)